Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolle...
| Authors: | ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Publication date: | 2010 |
| Country: | España |
| Institution: | Universidad Autónoma de Madrid |
| Repository: | Biblos-e Archivo. Repositorio Institucional de la UAM |
| Language: | English |
| OAI Identifier: | oai:repositorio.uam.es:10486/662397 |
| Online Access: | http://hdl.handle.net/10486/662397 https://dx.doi.org/10.1038/sj.bjc.6605663 |
| Access Level: | Open access |
| Keyword: | Aged Bevacizumab Capecitabine Colorectal neoplasms Neoplasm metastasis Medicina |
| _version_ | 1878736771744792576 |
|---|---|
| author | Feliú Batlle, Jaime |
| author2 | Safont, María José Salud, Antonieta T. Losa, Ferrán C. García-Girón, Carlos Bosch, Carles J A Escudero, Pilar López Manzanera, Rafael Madroñal, C. Bolaños, Margarita Gil, Mireia Llombart, Antonio C. Castro Carpeño, Francisco Javier de González Barón, Manuel |
| author2_role | author author author author author author author author author author author author author |
| author_browse | Bolaños, Margarita Bosch, Carles J A Castro Carpeño, Francisco Javier de Escudero, Pilar Feliú Batlle, Jaime García-Girón, Carlos Gil, Mireia González Barón, Manuel Llombart, Antonio C. Losa, Ferrán C. López Manzanera, Rafael Madroñal, C. Safont, María José Salud, Antonieta T. |
| author_facet | Feliú Batlle, Jaime Safont, María José Salud, Antonieta T. Losa, Ferrán C. García-Girón, Carlos Bosch, Carles J A Escudero, Pilar López Manzanera, Rafael Madroñal, C. Bolaños, Margarita Gil, Mireia Llombart, Antonio C. Castro Carpeño, Francisco Javier de González Barón, Manuel |
| author_role | author |
| collection | Biblos-e Archivo. Repositorio Institucional de la UAM |
| description | BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolled study. METHODS: Treatment consisted of capecitabine 1250 mgm 2 (or 950 mgm 2 for patients with a creatinine clearance of 30–50ml min 1) twice daily on days 1–14 and bevacizumab (7.5 mg kg 1) on day 1 every 3 weeks. RESULTS: A total of 59 patients aged X70 years with mCRC were enrolled. In an intention-to-treat analysis, the overall response rate was 34%, with 71% of patients achieving disease control. Median progression-free survival and overall survival were 10.8 months and 18 months, respectively. In all, 32 patients (54%) had grade 3/4 adverse events (AEs), the most common being hand–foot syndrome (19%), diarrhoea (9%) and deep venous thrombosis (7%). Four patients died because of treatment-related AEs. A relationship was detected between creatinine clearance p50 ml min 1 and the development of non-bevacizumab-related grade 3/4 AEs. The incidence of bevacizumab-associated AEs (hypertension, thromboembolic events and proteinuria) was consistent with that of previous reports in elderly patients. CONCLUSION: Bevacizumab combined with capecitabine represents a valid therapeutic alternative in elderly patients considered to be unsuitable for receiving polychemotherapy. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_950b2efc8c8d10c122db32edcb2b28ee |
| institution | Universidad Autónoma de Madrid |
| instname_str | Universidad Autónoma de Madrid |
| language | eng |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:repositorio.uam.es:10486/662397 |
| publishDate | 2010 |
| publishDateSort | 2010 |
| publisher | Nature Publishing Group |
| publisherStr | Nature Publishing Group |
| reponame_str | Biblos-e Archivo. Repositorio Institucional de la UAM |
| spelling | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer Feliú Batlle, Jaime Safont, María José Salud, Antonieta T. Losa, Ferrán C. García-Girón, Carlos Bosch, Carles J A Escudero, Pilar López Manzanera, Rafael Madroñal, C. Bolaños, Margarita Gil, Mireia Llombart, Antonio C. Castro Carpeño, Francisco Javier de González Barón, Manuel Aged Bevacizumab Capecitabine Colorectal neoplasms Neoplasm metastasis Medicina BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolled study. METHODS: Treatment consisted of capecitabine 1250 mgm 2 (or 950 mgm 2 for patients with a creatinine clearance of 30–50ml min 1) twice daily on days 1–14 and bevacizumab (7.5 mg kg 1) on day 1 every 3 weeks. RESULTS: A total of 59 patients aged X70 years with mCRC were enrolled. In an intention-to-treat analysis, the overall response rate was 34%, with 71% of patients achieving disease control. Median progression-free survival and overall survival were 10.8 months and 18 months, respectively. In all, 32 patients (54%) had grade 3/4 adverse events (AEs), the most common being hand–foot syndrome (19%), diarrhoea (9%) and deep venous thrombosis (7%). Four patients died because of treatment-related AEs. A relationship was detected between creatinine clearance p50 ml min 1 and the development of non-bevacizumab-related grade 3/4 AEs. The incidence of bevacizumab-associated AEs (hypertension, thromboembolic events and proteinuria) was consistent with that of previous reports in elderly patients. CONCLUSION: Bevacizumab combined with capecitabine represents a valid therapeutic alternative in elderly patients considered to be unsuitable for receiving polychemotherapy. This study was supported by Hoffmann-La Roche, Nutley, NJ, USA. Nature Publishing Group http://hdl.handle.net/10486/662397 https://dx.doi.org/10.1038/sj.bjc.6605663 |
| spellingShingle | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer Feliú Batlle, Jaime Aged Bevacizumab Capecitabine Colorectal neoplasms Neoplasm metastasis Medicina |
| title | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| title_full | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| title_fullStr | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| title_full_unstemmed | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| title_short | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| title_sort | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| topic | Aged Bevacizumab Capecitabine Colorectal neoplasms Neoplasm metastasis Medicina |
| topic_facet | Aged Bevacizumab Capecitabine Colorectal neoplasms Neoplasm metastasis Medicina |
| url | http://hdl.handle.net/10486/662397 https://dx.doi.org/10.1038/sj.bjc.6605663 |